The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Induction chemotherapy (IC) docetaxel (T), cisplatin (P), 5-fluorouracil (F) (TPF), or TP followed by concomitant boost radiotherapy (R) with or without cetuximab (E) for functional organ preservation (FOP) of resectable laryngeal and hypopharyngeal cancer (LHSCC): First results of the phase II randomized DeLOS-II study.
Andreas Dietz
Honoraria - Mererono
Research Funding - Merck; Sanofi
Michael Flentje
No relevant relationships to disclose
Rudolf Hagen
No relevant relationships to disclose
Ulrike Bockmuehl
No relevant relationships to disclose
Oliver Koelbl
No relevant relationships to disclose
Volker Schilling
No relevant relationships to disclose
Georg Maschmeyer
Honoraria - Merck Serono
Ursula Schroeder
No relevant relationships to disclose
Christian Sittel
No relevant relationships to disclose
Martin Goerner
No relevant relationships to disclose
Thomas Lenarz
No relevant relationships to disclose
Jens Peter Klussmann
No relevant relationships to disclose
Orlando Guntinas-Lichius
No relevant relationships to disclose
Claudia Rudack
No relevant relationships to disclose
Sabine Reinisch
No relevant relationships to disclose
Thomas Foerg
No relevant relationships to disclose
Martin Westhofen
No relevant relationships to disclose
Hans Juergen Welkoborsky
No relevant relationships to disclose
Dirk Esser
No relevant relationships to disclose
Ulrich Keilholz
Honoraria - Merck Serono; Sanofi